This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MDCO Medicines (MDCO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Medicines Stock (NASDAQ:MDCO) 30 days 90 days 365 days Advanced Chart Get Medicines alerts:Sign Up Key Stats Today's Range$84.90▼$84.9050-Day Range$84.90▼$84.9052-Week Range$17.81▼$84.98VolumeN/AAverage Volume9.55 million shsMarket Capitalization$6.77 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewThe Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.Read More… Receive MDCO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address MDCO Stock News HeadlinesFDA panel debates COVID vaccine recipe as questions swirl about fall shotsGovernment vaccine advisers are meeting to decide if the recipe for COVID-19 vaccines needs updating for this fall and winterMay 22 at 8:54 AM | marketbeat.comGSK’s Blenrep Receives Positive CHMP Opinion for Multiple Myeloma TreatmentMay 23 at 7:50 AM | tipranks.comMusk’s AI Masterplan – Our #1 AI Stock to Buy NowMissed Nvidia? This Under-the-Radar AI Stock Could Be Next Musk's AI empire is just beginning — and one overlooked company could be at the center of it all. We reveal everything in this exclusive Memorial Day webinar.May 24, 2025 | Behind the Markets (Ad)Soleno Therapeutics' Marketing Authorization Application for Diazoxide Choline Tablets Validated by European Medicines Agency for Prader-Willi Syndrome TreatmentMay 22 at 6:16 PM | quiverquant.comBioArctic Gains EU Orphan Designation for MSA TreatmentMay 22 at 9:35 AM | tipranks.com4SC AG Faces Setback as EMA Signals Negative Opinion on ResminostatMay 20, 2025 | tipranks.comAlligator Bioscience Secures Pediatric Study Waiver for MitazalimabMay 20, 2025 | tipranks.comPraxis Precision Medicines to Participate in Upcoming ConferencesMay 20, 2025 | investing.comSee More Headlines MDCO Stock Analysis - Frequently Asked Questions How were Medicines' earnings last quarter? The Medicines Company (NASDAQ:MDCO) issued its earnings results on Wednesday, October, 30th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by $0.12. What other stocks do shareholders of Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medicines investors own include Bristol-Myers Squibb (BMY), NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), AbbVie (ABBV), Alibaba Group (BABA) and Salesforce (CRM). Company Calendar Last Earnings10/30/2019Today5/23/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MDCO CIK1113481 Webwww.themedicinescompany.com Phone973-290-6000FaxN/AEmployees62Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,160,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-25.70% Debt Debt-to-Equity Ratio21.45 Current Ratio0.77 Quick Ratio0.77 Sales & Book Value Annual Sales$6.14 million Price / Sales1,102.36 Cash FlowN/A Price / Cash FlowN/A Book Value($0.30) per share Price / Book-283.00Miscellaneous Outstanding Shares79,723,000Free FloatN/AMarket Cap$6.77 billion OptionableOptionable Beta1.10 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:MDCO) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding The Medicines Company Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.